The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Emerging Cancer Diagnostics Market Research Report 2025
Synopsis
Cancer diagnosis frequently requires imaging studies that in many cases use small amounts of radiation.
The global Emerging Cancer Diagnostics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Emerging Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Emerging Cancer Diagnostics.
Report Scope
The Emerging Cancer Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Emerging Cancer Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Emerging Cancer Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Abbott Laboratories
Danaher
Agilent Technologies
AstraZeneca
BD
Biocept
Illumina
Luminex
NeoGenomics
QIAGEN
Thermo Fisher Scientific
Segment by Type
Men
Women
Segment by Application
Blood Cancer
Prostate Cancer
Breast Cancer
Lung Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Emerging Cancer Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Cancer diagnosis frequently requires imaging studies that in many cases use small amounts of radiation.
The global Emerging Cancer Diagnostics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Emerging Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Emerging Cancer Diagnostics.
Report Scope
The Emerging Cancer Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Emerging Cancer Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Emerging Cancer Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Abbott Laboratories
Danaher
Agilent Technologies
AstraZeneca
BD
Biocept
Illumina
Luminex
NeoGenomics
QIAGEN
Thermo Fisher Scientific
Segment by Type
Men
Women
Segment by Application
Blood Cancer
Prostate Cancer
Breast Cancer
Lung Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Emerging Cancer Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Emerging Cancer Diagnostics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Men
1.2.3 Women
1.3 Market by Application
1.3.1 Global Emerging Cancer Diagnostics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Blood Cancer
1.3.3 Prostate Cancer
1.3.4 Breast Cancer
1.3.5 Lung Cancer
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Emerging Cancer Diagnostics Market Perspective (2019-2030)
2.2 Emerging Cancer Diagnostics Growth Trends by Region
2.2.1 Global Emerging Cancer Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Emerging Cancer Diagnostics Historic Market Size by Region (2019-2024)
2.2.3 Emerging Cancer Diagnostics Forecasted Market Size by Region (2025-2030)
2.3 Emerging Cancer Diagnostics Market Dynamics
2.3.1 Emerging Cancer Diagnostics Industry Trends
2.3.2 Emerging Cancer Diagnostics Market Drivers
2.3.3 Emerging Cancer Diagnostics Market Challenges
2.3.4 Emerging Cancer Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Emerging Cancer Diagnostics Players by Revenue
3.1.1 Global Top Emerging Cancer Diagnostics Players by Revenue (2019-2024)
3.1.2 Global Emerging Cancer Diagnostics Revenue Market Share by Players (2019-2024)
3.2 Global Emerging Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Emerging Cancer Diagnostics Revenue
3.4 Global Emerging Cancer Diagnostics Market Concentration Ratio
3.4.1 Global Emerging Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Emerging Cancer Diagnostics Revenue in 2023
3.5 Emerging Cancer Diagnostics Key Players Head office and Area Served
3.6 Key Players Emerging Cancer Diagnostics Product Solution and Service
3.7 Date of Enter into Emerging Cancer Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Emerging Cancer Diagnostics Breakdown Data by Type
4.1 Global Emerging Cancer Diagnostics Historic Market Size by Type (2019-2024)
4.2 Global Emerging Cancer Diagnostics Forecasted Market Size by Type (2025-2030)
5 Emerging Cancer Diagnostics Breakdown Data by Application
5.1 Global Emerging Cancer Diagnostics Historic Market Size by Application (2019-2024)
5.2 Global Emerging Cancer Diagnostics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Emerging Cancer Diagnostics Market Size (2019-2030)
6.2 North America Emerging Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Emerging Cancer Diagnostics Market Size by Country (2019-2024)
6.4 North America Emerging Cancer Diagnostics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Emerging Cancer Diagnostics Market Size (2019-2030)
7.2 Europe Emerging Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Emerging Cancer Diagnostics Market Size by Country (2019-2024)
7.4 Europe Emerging Cancer Diagnostics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Emerging Cancer Diagnostics Market Size (2019-2030)
8.2 Asia-Pacific Emerging Cancer Diagnostics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Emerging Cancer Diagnostics Market Size by Region (2019-2024)
8.4 Asia-Pacific Emerging Cancer Diagnostics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Emerging Cancer Diagnostics Market Size (2019-2030)
9.2 Latin America Emerging Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Emerging Cancer Diagnostics Market Size by Country (2019-2024)
9.4 Latin America Emerging Cancer Diagnostics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Emerging Cancer Diagnostics Market Size (2019-2030)
10.2 Middle East & Africa Emerging Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Emerging Cancer Diagnostics Market Size by Country (2019-2024)
10.4 Middle East & Africa Emerging Cancer Diagnostics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Detail
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Emerging Cancer Diagnostics Introduction
11.1.4 Abbott Laboratories Revenue in Emerging Cancer Diagnostics Business (2019-2024)
11.1.5 Abbott Laboratories Recent Development
11.2 Danaher
11.2.1 Danaher Company Detail
11.2.2 Danaher Business Overview
11.2.3 Danaher Emerging Cancer Diagnostics Introduction
11.2.4 Danaher Revenue in Emerging Cancer Diagnostics Business (2019-2024)
11.2.5 Danaher Recent Development
11.3 Agilent Technologies
11.3.1 Agilent Technologies Company Detail
11.3.2 Agilent Technologies Business Overview
11.3.3 Agilent Technologies Emerging Cancer Diagnostics Introduction
11.3.4 Agilent Technologies Revenue in Emerging Cancer Diagnostics Business (2019-2024)
11.3.5 Agilent Technologies Recent Development
11.4 AstraZeneca
11.4.1 AstraZeneca Company Detail
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca Emerging Cancer Diagnostics Introduction
11.4.4 AstraZeneca Revenue in Emerging Cancer Diagnostics Business (2019-2024)
11.4.5 AstraZeneca Recent Development
11.5 BD
11.5.1 BD Company Detail
11.5.2 BD Business Overview
11.5.3 BD Emerging Cancer Diagnostics Introduction
11.5.4 BD Revenue in Emerging Cancer Diagnostics Business (2019-2024)
11.5.5 BD Recent Development
11.6 Biocept
11.6.1 Biocept Company Detail
11.6.2 Biocept Business Overview
11.6.3 Biocept Emerging Cancer Diagnostics Introduction
11.6.4 Biocept Revenue in Emerging Cancer Diagnostics Business (2019-2024)
11.6.5 Biocept Recent Development
11.7 Illumina
11.7.1 Illumina Company Detail
11.7.2 Illumina Business Overview
11.7.3 Illumina Emerging Cancer Diagnostics Introduction
11.7.4 Illumina Revenue in Emerging Cancer Diagnostics Business (2019-2024)
11.7.5 Illumina Recent Development
11.8 Luminex
11.8.1 Luminex Company Detail
11.8.2 Luminex Business Overview
11.8.3 Luminex Emerging Cancer Diagnostics Introduction
11.8.4 Luminex Revenue in Emerging Cancer Diagnostics Business (2019-2024)
11.8.5 Luminex Recent Development
11.9 NeoGenomics
11.9.1 NeoGenomics Company Detail
11.9.2 NeoGenomics Business Overview
11.9.3 NeoGenomics Emerging Cancer Diagnostics Introduction
11.9.4 NeoGenomics Revenue in Emerging Cancer Diagnostics Business (2019-2024)
11.9.5 NeoGenomics Recent Development
11.10 QIAGEN
11.10.1 QIAGEN Company Detail
11.10.2 QIAGEN Business Overview
11.10.3 QIAGEN Emerging Cancer Diagnostics Introduction
11.10.4 QIAGEN Revenue in Emerging Cancer Diagnostics Business (2019-2024)
11.10.5 QIAGEN Recent Development
11.11 Thermo Fisher Scientific
11.11.1 Thermo Fisher Scientific Company Detail
11.11.2 Thermo Fisher Scientific Business Overview
11.11.3 Thermo Fisher Scientific Emerging Cancer Diagnostics Introduction
11.11.4 Thermo Fisher Scientific Revenue in Emerging Cancer Diagnostics Business (2019-2024)
11.11.5 Thermo Fisher Scientific Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Emerging Cancer Diagnostics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Men
Table 3. Key Players of Women
Table 4. Global Emerging Cancer Diagnostics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Emerging Cancer Diagnostics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Emerging Cancer Diagnostics Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Emerging Cancer Diagnostics Market Share by Region (2019-2024)
Table 8. Global Emerging Cancer Diagnostics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Emerging Cancer Diagnostics Market Share by Region (2025-2030)
Table 10. Emerging Cancer Diagnostics Market Trends
Table 11. Emerging Cancer Diagnostics Market Drivers
Table 12. Emerging Cancer Diagnostics Market Challenges
Table 13. Emerging Cancer Diagnostics Market Restraints
Table 14. Global Emerging Cancer Diagnostics Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Emerging Cancer Diagnostics Market Share by Players (2019-2024)
Table 16. Global Top Emerging Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Emerging Cancer Diagnostics as of 2023)
Table 17. Ranking of Global Top Emerging Cancer Diagnostics Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Emerging Cancer Diagnostics Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Emerging Cancer Diagnostics Product Solution and Service
Table 21. Date of Enter into Emerging Cancer Diagnostics Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Emerging Cancer Diagnostics Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Emerging Cancer Diagnostics Revenue Market Share by Type (2019-2024)
Table 25. Global Emerging Cancer Diagnostics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Emerging Cancer Diagnostics Revenue Market Share by Type (2025-2030)
Table 27. Global Emerging Cancer Diagnostics Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Emerging Cancer Diagnostics Revenue Market Share by Application (2019-2024)
Table 29. Global Emerging Cancer Diagnostics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Emerging Cancer Diagnostics Revenue Market Share by Application (2025-2030)
Table 31. North America Emerging Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Emerging Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Emerging Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Emerging Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Emerging Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Emerging Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Emerging Cancer Diagnostics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Emerging Cancer Diagnostics Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Emerging Cancer Diagnostics Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Emerging Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Emerging Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Emerging Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Emerging Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Emerging Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Emerging Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 46. Abbott Laboratories Company Detail
Table 47. Abbott Laboratories Business Overview
Table 48. Abbott Laboratories Emerging Cancer Diagnostics Product
Table 49. Abbott Laboratories Revenue in Emerging Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 50. Abbott Laboratories Recent Development
Table 51. Danaher Company Detail
Table 52. Danaher Business Overview
Table 53. Danaher Emerging Cancer Diagnostics Product
Table 54. Danaher Revenue in Emerging Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 55. Danaher Recent Development
Table 56. Agilent Technologies Company Detail
Table 57. Agilent Technologies Business Overview
Table 58. Agilent Technologies Emerging Cancer Diagnostics Product
Table 59. Agilent Technologies Revenue in Emerging Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 60. Agilent Technologies Recent Development
Table 61. AstraZeneca Company Detail
Table 62. AstraZeneca Business Overview
Table 63. AstraZeneca Emerging Cancer Diagnostics Product
Table 64. AstraZeneca Revenue in Emerging Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 65. AstraZeneca Recent Development
Table 66. BD Company Detail
Table 67. BD Business Overview
Table 68. BD Emerging Cancer Diagnostics Product
Table 69. BD Revenue in Emerging Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 70. BD Recent Development
Table 71. Biocept Company Detail
Table 72. Biocept Business Overview
Table 73. Biocept Emerging Cancer Diagnostics Product
Table 74. Biocept Revenue in Emerging Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 75. Biocept Recent Development
Table 76. Illumina Company Detail
Table 77. Illumina Business Overview
Table 78. Illumina Emerging Cancer Diagnostics Product
Table 79. Illumina Revenue in Emerging Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 80. Illumina Recent Development
Table 81. Luminex Company Detail
Table 82. Luminex Business Overview
Table 83. Luminex Emerging Cancer Diagnostics Product
Table 84. Luminex Revenue in Emerging Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 85. Luminex Recent Development
Table 86. NeoGenomics Company Detail
Table 87. NeoGenomics Business Overview
Table 88. NeoGenomics Emerging Cancer Diagnostics Product
Table 89. NeoGenomics Revenue in Emerging Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 90. NeoGenomics Recent Development
Table 91. QIAGEN Company Detail
Table 92. QIAGEN Business Overview
Table 93. QIAGEN Emerging Cancer Diagnostics Product
Table 94. QIAGEN Revenue in Emerging Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 95. QIAGEN Recent Development
Table 96. Thermo Fisher Scientific Company Detail
Table 97. Thermo Fisher Scientific Business Overview
Table 98. Thermo Fisher Scientific Emerging Cancer Diagnostics Product
Table 99. Thermo Fisher Scientific Revenue in Emerging Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 100. Thermo Fisher Scientific Recent Development
Table 101. Research Programs/Design for This Report
Table 102. Key Data Information from Secondary Sources
Table 103. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Emerging Cancer Diagnostics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Emerging Cancer Diagnostics Market Share by Type: 2023 VS 2030
Figure 3. Men Features
Figure 4. Women Features
Figure 5. Global Emerging Cancer Diagnostics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Emerging Cancer Diagnostics Market Share by Application: 2023 VS 2030
Figure 7. Blood Cancer Case Studies
Figure 8. Prostate Cancer Case Studies
Figure 9. Breast Cancer Case Studies
Figure 10. Lung Cancer Case Studies
Figure 11. Others Case Studies
Figure 12. Emerging Cancer Diagnostics Report Years Considered
Figure 13. Global Emerging Cancer Diagnostics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Emerging Cancer Diagnostics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Emerging Cancer Diagnostics Market Share by Region: 2023 VS 2030
Figure 16. Global Emerging Cancer Diagnostics Market Share by Players in 2023
Figure 17. Global Top Emerging Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Emerging Cancer Diagnostics as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Emerging Cancer Diagnostics Revenue in 2023
Figure 19. North America Emerging Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Emerging Cancer Diagnostics Market Share by Country (2019-2030)
Figure 21. United States Emerging Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Emerging Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Emerging Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Emerging Cancer Diagnostics Market Share by Country (2019-2030)
Figure 25. Germany Emerging Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Emerging Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Emerging Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Emerging Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Emerging Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Emerging Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Emerging Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Emerging Cancer Diagnostics Market Share by Region (2019-2030)
Figure 33. China Emerging Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Emerging Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Emerging Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Emerging Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Emerging Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Emerging Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Emerging Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Emerging Cancer Diagnostics Market Share by Country (2019-2030)
Figure 41. Mexico Emerging Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Emerging Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Emerging Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Emerging Cancer Diagnostics Market Share by Country (2019-2030)
Figure 45. Turkey Emerging Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Emerging Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Abbott Laboratories Revenue Growth Rate in Emerging Cancer Diagnostics Business (2019-2024)
Figure 48. Danaher Revenue Growth Rate in Emerging Cancer Diagnostics Business (2019-2024)
Figure 49. Agilent Technologies Revenue Growth Rate in Emerging Cancer Diagnostics Business (2019-2024)
Figure 50. AstraZeneca Revenue Growth Rate in Emerging Cancer Diagnostics Business (2019-2024)
Figure 51. BD Revenue Growth Rate in Emerging Cancer Diagnostics Business (2019-2024)
Figure 52. Biocept Revenue Growth Rate in Emerging Cancer Diagnostics Business (2019-2024)
Figure 53. Illumina Revenue Growth Rate in Emerging Cancer Diagnostics Business (2019-2024)
Figure 54. Luminex Revenue Growth Rate in Emerging Cancer Diagnostics Business (2019-2024)
Figure 55. NeoGenomics Revenue Growth Rate in Emerging Cancer Diagnostics Business (2019-2024)
Figure 56. QIAGEN Revenue Growth Rate in Emerging Cancer Diagnostics Business (2019-2024)
Figure 57. Thermo Fisher Scientific Revenue Growth Rate in Emerging Cancer Diagnostics Business (2019-2024)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
